Bausch & Lomb Incorporated

🇺🇸United States
Ownership
-
Established
1992-10-08
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome

Phase 2
Completed
Conditions
Dry Eye Syndromes
Interventions
Drug: Placebo
Drug: Ecabet
First Posted Date
2006-09-01
Last Posted Date
2013-03-15
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
162
Registration Number
NCT00370747

A Study to Investigate the Safety and Effectiveness of Aspheric Laser Refractive Surgery Treatments for Myopia

First Posted Date
2006-08-17
Last Posted Date
2011-12-08
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
127
Registration Number
NCT00365677

A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.

Phase 3
Completed
Conditions
Acute Bacterial Conjunctivitis
Interventions
Drug: Vehicle
Drug: ISV-403
First Posted Date
2006-07-04
Last Posted Date
2015-03-24
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
957
Registration Number
NCT00347932

A Clinical Evaluation of the Next Generation Diagnostic Instrument (NGDI)

First Posted Date
2006-07-04
Last Posted Date
2014-01-17
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
76
Registration Number
NCT00347594
Locations
🇺🇸

Bausch & Lomb, Rochester, New York, United States

A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)

Phase 1
Terminated
Conditions
Vitreoretinal Traction Syndrome
Interventions
Drug: Plasmin
First Posted Date
2006-07-04
Last Posted Date
2019-06-21
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
4
Registration Number
NCT00347646
Locations
🇺🇸

University Hospitals of Cleveland, Cleveland, Ohio, United States

Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment

Phase 2
Terminated
Conditions
Vitreoretinal Traction Syndrome
Interventions
Drug: Vehicle
Drug: Plasmin
First Posted Date
2006-07-04
Last Posted Date
2019-06-21
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
29
Registration Number
NCT00348439
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

A Study to Evaluate the Safety and Effectiveness of the 217z Laser With Zyoptix for Lasik

Not Applicable
Withdrawn
Conditions
Myopia
Astigmatism
Interventions
Device: 217z Laser
First Posted Date
2006-07-04
Last Posted Date
2011-12-08
Lead Sponsor
Bausch & Lomb Incorporated
Registration Number
NCT00347997

A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis

First Posted Date
2006-07-04
Last Posted Date
2015-03-24
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
1161
Registration Number
NCT00348348

A Study to Evaluate the Safety and Effectiveness of the Technols 217z Zyoptix System for Hyperopia

Not Applicable
Completed
Conditions
Hyperopia
Astigmatism
Interventions
Device: Technolas 217z Zyoptix Laser
First Posted Date
2006-07-04
Last Posted Date
2020-09-14
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
80
Registration Number
NCT00348205
Locations
🇺🇸

Bausch & Lomb, Rochester, New York, United States

Safety/Efficacy of Bromfenac Ophthalmic Solution for Ocular Inflammation and Pain Associated With Cataract Surgery

First Posted Date
2006-06-06
Last Posted Date
2013-02-15
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
522
Registration Number
NCT00333918
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy